Sökning: WFRF:(Neto Pedro R.) > Stage-specific link...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07423naa a2200637 4500 | |
001 | oai:lup.lub.lu.se:05ffe189-2a51-482b-bd81-07397840db30 | |
003 | SwePub | |
008 | 210210s2020 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/299140 | |
024 | 7 | a https://lup.lub.lu.se/record/05ffe189-2a51-482b-bd81-07397840db302 URI |
024 | 7 | a https://doi.org/10.1093/brain/awaa3422 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/2991402 URI |
040 | a (SwePub)lud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Lessa Benedet, Andréau Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xlesan |
245 | 1 0 | a Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease |
264 | c 2020-11-19 | |
264 | 1 | b Oxford University Press (OUP),c 2020 |
300 | a 12 s. | |
520 | a Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of Alzheimer's disease. It remains uncertain, however, how it relates to amyloid and tau pathology or neurodegeneration across the Alzheimer's disease continuum. The aim of this study was to investigate how plasma NfL relates to amyloid and tau PET and MRI measures of brain atrophy in participants with and without cognitive impairment. We retrospectively examined the association between plasma NfL and MRI measures of grey/white matter volumes in the Alzheimer's Disease Neuroimaging Initiative [ADNI: n = 1149; 382 cognitively unimpaired control subjects and 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer's disease dementia n = 347)]. Longitudinal plasma NfL was measured using single molecule array (Simoa) technology. Cross-sectional associations between plasma NfL and PET amyloid and tau measures were independently assessed in two cohorts: ADNI [n = 198; 110 cognitively unimpaired, 88 cognitively impaired (MCI n = 67, Alzheimer's disease dementia n = 21), data accessed October 2018]; and Translational Biomarkers in Aging and Dementia [TRIAD, n = 116; 74 cognitively unimpaired, 42 cognitively impaired (MCI n = 16, Alzheimer's disease dementia n = 26), data obtained November 2017 to January 2019]. Associations between plasma NfL and imaging-derived measures were examined voxel-wise using linear regression (cross-sectional) and linear mixed effect models (longitudinal). Cross-sectional analyses in both cohorts showed that plasma NfL was associated with PET findings in brain regions typically affected by Alzheimer's disease; associations were specific to amyloid PET in cognitively unimpaired and tau PET in cognitively impaired (P < 0.05). Longitudinal analyses showed that NfL levels were associated with grey/white matter volume loss; grey matter atrophy in cognitively unimpaired was specific to APOE ϵ4 carriers (P < 0.05). These findings suggest that plasma NfL increases in response to amyloid-related neuronal injury in preclinical stages of Alzheimer's disease, but is related to tau-mediated neurodegeneration in symptomatic patients. As such, plasma NfL may a useful measure to monitor effects in disease-modifying drug trials. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
653 | a Alzheimer's disease | |
653 | a amyloid | |
653 | a MRI | |
653 | a neurofilament light | |
653 | a tau | |
700 | 1 | a Leuzy, Antoineu Gothenburg University,Göteborgs universitet,Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xleuan |
700 | 1 | a Pascoal, Tharick A.u McGill University4 aut |
700 | 1 | a Ashton, Nicholas J.u Gothenburg University,Göteborgs universitet,University of Gothenburg,King's College London,South London and Maudsley NHS Foundation Trust,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xashtn |
700 | 1 | a Mathotaarachchi, Sulanthau McGill University4 aut |
700 | 1 | a Savard, Melissau McGill University4 aut |
700 | 1 | a Therriault, Josephu McGill University4 aut |
700 | 1 | a Kang, Min Suu McGill University4 aut |
700 | 1 | a Chamoun, Mirau McGill University4 aut |
700 | 1 | a Schöll, Michaelu Gothenburg University,Göteborgs universitet,University of Gothenburg,Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,University College London,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xschom |
700 | 1 | a Zimmer, Eduardo R.u Federal University of Rio Grande do Sul,McGill University4 aut |
700 | 1 | a Gauthier, Sergeu McGill University4 aut |
700 | 1 | a Labbe, Aurélieu HEC Montreal4 aut |
700 | 1 | a Zetterberg, Henriku Gothenburg University,Göteborgs universitet,University of Gothenburg,University College London,Sahlgrenska University Hospital,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe |
700 | 1 | a Rosa-Neto, Pedrou Montreal Neurological Institute & Hospital,McGill University4 aut |
700 | 1 | a Blennow, Kaju Gothenburg University,Göteborgs universitet,University of Gothenburg,Sahlgrenska University Hospital,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Braind : Oxford University Press (OUP)g 143:12, s. 3793-3804q 143:12<3793-3804x 0006-8950x 1460-2156 |
856 | 4 | u http://dx.doi.org/10.1093/brain/awaa342y FULLTEXT |
856 | 4 | u https://academic.oup.com/brain/article-pdf/143/12/3793/36123625/awaa342.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/05ffe189-2a51-482b-bd81-07397840db30 |
856 | 4 8 | u https://doi.org/10.1093/brain/awaa342 |
856 | 4 8 | u https://gup.ub.gu.se/publication/299140 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.